highest degree of uncertainty and risk. These early-phase trials require precise operational planning, stringent safety monitoring, and proactive communication. Operational risk management in FIH trials is essential to protect participants, ensure data integrity, and enable efficient dose escalation decisions. This guide provides a practical framework for identifying, mitigating, and managing operational risks in FIH clinical trials.

Unique Operational Risks in FIH Trials

• Unknown safety profile: Human exposure for the first time with no clinical precedent
• High variability in PK/PD: Makes dosing decisions complex
• Site and staff readiness: Need specialized training and 24/7 monitoring capability
• Complex data review: Requires real-time assessment of emerging safety data

Key Components of FIH Operational Risk Management

1. Site Selection and Qualification

• Choose sites with experience in FIH trials and 24-hour medical oversight
• Confirm access to emergency services and intensive care facilities

2. Investigator Training and Certification

• Train PI and sub-investigators on molecule-specific risks
• Simulate emergency protocols before first dosing

3. Safety Monitoring Infrastructure

• Use telemetry, ECG, and vital sign monitoring during initial dosing
• Ensure 1:1 nurse-to-volunteer ratio for high-risk molecules

4. Sentinel Dosing Strategy

• Dose first 1–2 subjects with sufficient observation period
• Evaluate real-time safety data before proceeding with rest of cohort

5. Dose Escalation Governance

• Implement predefined stopping rules and decision matrices
• Conduct Safety Review Committee (SRC) meetings after each cohort

6. Emergency Response Protocols

• Have resuscitation equipment on-site and validated
• Ensure unblinding SOPs and AE response teams are available

Real-Time Data Flow

• Use centralized EDC and data monitoring dashboards
• Trigger automated alerts for Grade ≥2 AEs, QTc prolongation, or lab abnormalities

Regulatory Expectations

FDA

• Requires communication of FIH operational plans in IND
• Supports real-time monitoring and safety governance structures

EMA

• EMA guideline on strategies for FIH trials (2018) emphasizes risk-based study design
• Demands description of operational mitigations for high-risk compounds

CDSCO

• Requires investigator site readiness certification
• Demands emergency response plans in clinical trial protocol

Communication and Oversight

• Daily safety huddles during active dosing periods
• Assign roles for risk reporting, communication, and escalation pathways
• Ensure GCP-compliant documentation of all decisions

Best Practices

• Develop a comprehensive Risk Management Plan (RMP) before trial starts
• Use mock drills and simulations to validate procedures
• Schedule pre-dose dry runs for every SAD and MAD cohort
• Define clear communication channels between CRO, sponsor, and PI